Common regimens include salvage chemotherapy with FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (G-CSF)), MEC (mitoxantrone, etoposide, and cytarabine), or CLAG (cladribine, cytarabine, and G-CSF) and targeted agents (if applicable) such as FLT3 inhibitors (e.g., gilteritinib) for FLT3-mutated AML and IDH1/IDH2 inhibitors (e.g., ivosidenib or enasidenib) for IDH-mutated disease [7]. This evidence concerns the gene IDH2 and acute myeloid leukemia.